Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma
Marc Massanari(Novartis (United States)), Robert K. Zeldin(Musicians Emergency Fund), Gregory P. Geba(Regeneron (United States)), Harold S. Nelson(National Jewish Health), Farid Kianifard, Thomas B. Casale(University of South Florida), William W. Busse(University of Wisconsin–Madison)
Cited by 230
Related Papers
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
|Journal of Allergy and Clinical Immunology|2001|1.3k
Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
|Journal of Allergy and Clinical Immunology|2011|1.2k